Lihi Eder1, Jessica Widdifield2, Cheryl F Rosen3, Richard Cook4, Ker-Ai Lee4, Raed Alhusayen5, Michael J Paterson2, Stephanie Y Cheng6, Shirin Jabbari6, Willemina Campbell7, Sasha Bernatsky8, Dafna D Gladman3, Karen Tu3. 1. University of Toronto and Women's College Hospital, Toronto, Ontario, Canada. 2. University of Toronto and Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada. 3. University of Toronto and Toronto Western Hospital, Toronto, Ontario, Canada. 4. University of Waterloo, Waterloo, Ontario, Canada. 5. University of Toronto and Sunnybrook Hospital, Toronto, Ontario, Canada. 6. Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada. 7. Patient Research Partner, Toronto Western Hospital, Toronto, Ontario, Canada. 8. McGill University Health Centre, Montreal, Quebec, Canada.
Abstract
OBJECTIVE: To estimate the prevalence and incidence of psoriasis and psoriatic arthritis (PsA) over time in Ontario, Canada. METHODS: We performed a population-based study of Ontario health administrative data, using validated case definitions for psoriasis and PsA. We computed the crude and age- and sex-standardized cumulative prevalence and incidence of psoriasis from 2000 to 2015. RESULTS: Among the 10,774,802 individuals ages ≥20 years residing in Ontario in 2015, we identified 273,238 patients with psoriasis and 18,655 patients with PsA, equating to cumulative prevalence estimates of 2.54% and 0.17%, respectively. Correcting the prevalence estimates for imperfect sensitivity and specificity resulted in similar estimates. The male:female ratio was approximately 1.0 for both conditions. For psoriasis, the age- and sex-standardized cumulative prevalence increased from 1.74% in 2000 to 2.32% in 2015. For PsA, the age- and sex-standardized cumulative prevalence increased from 0.09% in 2008 to 0.15% in 2015. Between 2008 and 2015, annual incidence rates for psoriasis decreased, whereas those for PsA remained relatively stable. CONCLUSION: The prevalence and incidence of psoriasis and PsA in Ontario are similar to those observed in Europe and the US. The steady increase in the prevalence of psoriasis and PsA over the past decade may be due to a combination of population aging, population growth, and increasing life expectancy.
OBJECTIVE: To estimate the prevalence and incidence of psoriasis and psoriatic arthritis (PsA) over time in Ontario, Canada. METHODS: We performed a population-based study of Ontario health administrative data, using validated case definitions for psoriasis and PsA. We computed the crude and age- and sex-standardized cumulative prevalence and incidence of psoriasis from 2000 to 2015. RESULTS: Among the 10,774,802 individuals ages ≥20 years residing in Ontario in 2015, we identified 273,238 patients with psoriasis and 18,655 patients with PsA, equating to cumulative prevalence estimates of 2.54% and 0.17%, respectively. Correcting the prevalence estimates for imperfect sensitivity and specificity resulted in similar estimates. The male:female ratio was approximately 1.0 for both conditions. For psoriasis, the age- and sex-standardized cumulative prevalence increased from 1.74% in 2000 to 2.32% in 2015. For PsA, the age- and sex-standardized cumulative prevalence increased from 0.09% in 2008 to 0.15% in 2015. Between 2008 and 2015, annual incidence rates for psoriasis decreased, whereas those for PsA remained relatively stable. CONCLUSION: The prevalence and incidence of psoriasis and PsA in Ontario are similar to those observed in Europe and the US. The steady increase in the prevalence of psoriasis and PsA over the past decade may be due to a combination of population aging, population growth, and increasing life expectancy.
Authors: Jürgen Rech; Michael Sticherling; Daniel Stoessel; Mona H C Biermann; Benjamin M Häberle; Maximilian Reinhardt Journal: Rheumatol Adv Pract Date: 2020-07-10
Authors: Alanna C Bridgman; Christina Fitzmaurice; Robert P Dellavalle; Chante Karimkhani Aksut; Ayman Grada; Mohsen Naghavi; Navid Manafi; Andrew T Olagunju; Tinuke O Olagunju; Ranjani Somayaji; Aaron M Drucker Journal: J Cutan Med Surg Date: 2020-01-29 Impact factor: 2.092
Authors: Rosa Parisi; Ireny Y K Iskandar; Evangelos Kontopantelis; Matthias Augustin; Christopher E M Griffiths; Darren M Ashcroft Journal: BMJ Date: 2020-05-28
Authors: C Lecaros; J Dunstan; F Villena; D M Ashcroft; R Parisi; C E M Griffiths; S Härtel; J T Maul; C De la Cruz Journal: Clin Exp Dermatol Date: 2021-06-26 Impact factor: 3.470